{
  "dataset": {
    "version": "2026-11-15",
    "sha256": "966d20e4ebd28b02a5bf5709b5733de3f33bebb38b66ba9885ad48a836deddd2",
    "counts": {
      "acts": 47,
      "concepts": 25,
      "edges": 28,
      "obligations": 29,
      "measures": 43,
      "gaps": 32,
      "mitigations": 13,
      "equivalences": 27
    },
    "ledger_seq": 421
  },
  "counts": {
    "eu_to_national": 19,
    "national_to_eu": 13
  },
  "gaps": [
    {
      "id": "gap.de.scr.prostate",
      "direction": "eu_to_national",
      "jurisdiction_code": "DE",
      "concept_id": "oncology.dx.screening.prostate",
      "obligation_id": "eu.scr.prostate",
      "measure_id": "de.scr.prostate",
      "gap_type": "divergent",
      "severity": 2,
      "summary": "Statutory early detection relies on clinical examination; PSA with MRI is not a covered screening pathway.",
      "verification": "needs_research",
      "status": "proposed",
      "reviewed_ledger_seq": null,
      "step": "Prostate cancer screening (PSA with MRI)",
      "obligation": {
        "id": "eu.scr.prostate",
        "article": "Point 2 (prostate)",
        "summary": "Evaluate organised prostate screening for men up to 70 based on PSA testing combined with MRI follow-up, stepwise, through research and pilots.",
        "act": {
          "act_id": "celex:32022H1214(01)",
          "title": "Council Recommendation of 9 December 2022 on strengthening prevention through early detection: a new EU approach on cancer screening (2022/C 473/01)",
          "short_title": "Council Rec. 2022 on cancer screening",
          "url": "https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32022H1214(01)",
          "binding": "non_binding"
        }
      },
      "measure": {
        "id": "de.scr.prostate",
        "article": "KFE-RL, prostate section",
        "summary": "Opportunistic early detection for men from 45 by clinical examination; PSA testing is not a statutory screening benefit and is usually paid privately.",
        "url": "https://www.g-ba.de/richtlinien/17/",
        "verification": "needs_research",
        "act": {
          "act_id": "de:gba-kfe-rl",
          "title": "G-BA Krebsfrüherkennungs-Richtlinie (KFE-RL)",
          "short_title": "G-BA Krebsfrüherkennungs-Richtlinie (KFE-RL)",
          "url": "https://www.g-ba.de/richtlinien/17/",
          "binding": "national"
        }
      },
      "mitigations": []
    },
    {
      "id": "gap.de.scr.cervical",
      "direction": "eu_to_national",
      "jurisdiction_code": "DE",
      "concept_id": "oncology.dx.screening.cervical",
      "obligation_id": "eu.scr.cervical",
      "measure_id": "de.scr.cervical",
      "gap_type": "divergent",
      "severity": 1,
      "summary": "Co-testing every three years from 35 and annual cytology from 20 differ from HPV-primary at five-year intervals from 30.",
      "verification": "needs_research",
      "status": "proposed",
      "reviewed_ledger_seq": null,
      "step": "Cervical cancer screening (HPV primary)",
      "obligation": {
        "id": "eu.scr.cervical",
        "article": "Point 1 and Annex (cervical)",
        "summary": "Offer HPV testing as the preferred primary test to women aged 30–65, at intervals of five years or more depending on vaccination history.",
        "act": {
          "act_id": "celex:32022H1214(01)",
          "title": "Council Recommendation of 9 December 2022 on strengthening prevention through early detection: a new EU approach on cancer screening (2022/C 473/01)",
          "short_title": "Council Rec. 2022 on cancer screening",
          "url": "https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32022H1214(01)",
          "binding": "non_binding"
        }
      },
      "measure": {
        "id": "de.scr.cervical",
        "article": "oKFE-RL, cervical programme",
        "summary": "Annual cytology for women 20–34; from 35 a combined HPV and cytology co-test every three years.",
        "url": "https://www.g-ba.de/richtlinien/104/",
        "verification": "needs_research",
        "act": {
          "act_id": "de:gba-okfe-rl",
          "title": "G-BA Richtlinie für organisierte Krebsfrüherkennungsprogramme (oKFE-RL): colorectal and cervical programmes",
          "short_title": "G-BA Richtlinie für organisierte Krebsfrüherkennungsprogramme (oKFE-RL): colorectal and cervical programmes",
          "url": "https://www.g-ba.de/richtlinien/104/",
          "binding": "national"
        }
      },
      "mitigations": []
    },
    {
      "id": "gap.de.scr.colorectal",
      "direction": "eu_to_national",
      "jurisdiction_code": "DE",
      "concept_id": "oncology.dx.screening.colorectal",
      "obligation_id": "eu.scr.colorectal",
      "measure_id": "de.scr.colorectal",
      "gap_type": "divergent",
      "severity": 1,
      "summary": "Primary screening colonoscopy is offered alongside FIT, while the Recommendation prefers FIT triage; detection rates are not directly comparable.",
      "verification": "needs_research",
      "status": "proposed",
      "reviewed_ledger_seq": null,
      "step": "Colorectal cancer screening (FIT)",
      "obligation": {
        "id": "eu.scr.colorectal",
        "article": "Point 1 and Annex (colorectal)",
        "summary": "Offer quantitative FIT screening to people aged 50–74 as the preferred triage test before endoscopic follow-up.",
        "act": {
          "act_id": "celex:32022H1214(01)",
          "title": "Council Recommendation of 9 December 2022 on strengthening prevention through early detection: a new EU approach on cancer screening (2022/C 473/01)",
          "short_title": "Council Rec. 2022 on cancer screening",
          "url": "https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32022H1214(01)",
          "binding": "non_binding"
        }
      },
      "measure": {
        "id": "de.scr.colorectal",
        "article": "oKFE-RL, colorectal programme",
        "summary": "Choice between FIT and screening colonoscopy from age 50, with invitations; primary colonoscopy is offered alongside FIT.",
        "url": "https://www.g-ba.de/richtlinien/104/",
        "verification": "needs_research",
        "act": {
          "act_id": "de:gba-okfe-rl",
          "title": "G-BA Richtlinie für organisierte Krebsfrüherkennungsprogramme (oKFE-RL): colorectal and cervical programmes",
          "short_title": "G-BA Richtlinie für organisierte Krebsfrüherkennungsprogramme (oKFE-RL): colorectal and cervical programmes",
          "url": "https://www.g-ba.de/richtlinien/104/",
          "binding": "national"
        }
      },
      "mitigations": []
    },
    {
      "id": "gap.de.scr.gastric",
      "direction": "eu_to_national",
      "jurisdiction_code": "DE",
      "concept_id": "oncology.dx.screening.gastric",
      "obligation_id": "eu.scr.gastric",
      "measure_id": null,
      "gap_type": "not_applicable",
      "severity": 0,
      "summary": "No programme; Germany is not a high-incidence setting, so the recommendation has limited scope.",
      "verification": "needs_research",
      "status": "proposed",
      "reviewed_ledger_seq": null,
      "step": "Gastric cancer screening (H. pylori screen-and-treat)",
      "obligation": {
        "id": "eu.scr.gastric",
        "article": "Point 2 (gastric)",
        "summary": "Consider H. pylori screen-and-treat in countries or regions with high gastric cancer incidence and mortality, and surveillance of pre-cancerous lesions.",
        "act": {
          "act_id": "celex:32022H1214(01)",
          "title": "Council Recommendation of 9 December 2022 on strengthening prevention through early detection: a new EU approach on cancer screening (2022/C 473/01)",
          "short_title": "Council Rec. 2022 on cancer screening",
          "url": "https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32022H1214(01)",
          "binding": "non_binding"
        }
      },
      "measure": null,
      "mitigations": []
    },
    {
      "id": "gap.de.gendg",
      "direction": "national_to_eu",
      "jurisdiction_code": "DE",
      "concept_id": "oncology.dx.biomarker.germline",
      "obligation_id": "eu.gdpr.health",
      "measure_id": "de.gen.gendg",
      "gap_type": "exceeds",
      "severity": 2,
      "summary": "German genetic testing law adds physician-only testing, written consent and mandatory counselling that are not harmonised at EU level (allowed under GDPR Art. 9(4)). Results or consent obtained abroad may not satisfy GenDG.",
      "verification": "cited_unverified",
      "status": "proposed",
      "reviewed_ledger_seq": null,
      "step": "Germline genetic testing for hereditary cancer",
      "obligation": {
        "id": "eu.gdpr.health",
        "article": "Art. 9(2)(h)–(j) and Art. 89",
        "summary": "Health and genetic data are special categories; processing needs an Art. 9(2) condition, and research needs Art. 89 safeguards. Member States may keep further conditions for genetic and health data (Art. 9(4)).",
        "act": {
          "act_id": "celex:32016R0679",
          "title": "Regulation (EU) 2016/679 General Data Protection Regulation (GDPR)",
          "short_title": "Reg. 2016/679 (GDPR)",
          "url": "https://eur-lex.europa.eu/eli/reg/2016/679/oj",
          "binding": "directly_applicable"
        }
      },
      "measure": {
        "id": "de.gen.gendg",
        "article": "§§ 7–10 GenDG",
        "summary": "Diagnostic genetic tests only by physicians, after written informed consent, with genetic counselling for predictive tests; strict rules on use of results.",
        "url": "https://www.gesetze-im-internet.de/gendg/",
        "verification": "cited_unverified",
        "act": {
          "act_id": "de:gendg",
          "title": "Gendiagnostikgesetz (GenDG, 2009)",
          "short_title": "Gendiagnostikgesetz (GenDG, 2009)",
          "url": "https://www.gesetze-im-internet.de/gendg/",
          "binding": "national"
        }
      },
      "mitigations": [
        {
          "id": "mit.de.gendg",
          "gap_id": "gap.de.gendg",
          "kind": "research",
          "audience": "researchers",
          "summary": "Use a consent and counselling template that satisfies GenDG to make germline data from all three countries reusable in one study.",
          "reference_measure_id": null
        }
      ]
    },
    {
      "id": "gap.de.lung.ahead",
      "direction": "national_to_eu",
      "jurisdiction_code": "DE",
      "concept_id": "oncology.dx.screening.lung",
      "obligation_id": "eu.scr.lung",
      "measure_id": "de.scr.lung",
      "gap_type": "exceeds",
      "severity": 1,
      "summary": "Germany has a legal basis and a statutory benefit for LDCT lung screening, ahead of the EU's stepwise-evaluation stage. Cross-border: a patient from another state cannot use the Directive route to claim LDCT screening unless their home system covers it.",
      "verification": "verified",
      "status": "proposed",
      "reviewed_ledger_seq": null,
      "step": "Lung cancer screening (low-dose CT)",
      "obligation": {
        "id": "eu.scr.lung",
        "article": "Point 2 (lung)",
        "summary": "Explore the feasibility and effectiveness of low-dose CT screening for heavy smokers and ex-smokers, stepwise, starting with research and pilots and linked to smoking cessation.",
        "act": {
          "act_id": "celex:32022H1214(01)",
          "title": "Council Recommendation of 9 December 2022 on strengthening prevention through early detection: a new EU approach on cancer screening (2022/C 473/01)",
          "short_title": "Council Rec. 2022 on cancer screening",
          "url": "https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32022H1214(01)",
          "binding": "non_binding"
        }
      },
      "measure": {
        "id": "de.scr.lung",
        "article": "LuKrFrühErkV (§ 84 StrlSchG) and G-BA KFE-RL decision of 18 June 2025",
        "summary": "Ordinance permitting low-dose CT for early detection of lung cancer in heavy smokers, followed by a G-BA decision making it a statutory health insurance benefit for heavy smokers aged 50–75.",
        "url": "https://www.g-ba.de/downloads/39-261-7301/2025-06-18_KFE-RL_Einf-Lungenkrebsfrueherkennung-Niedrigdosis-CT-Raucher.pdf",
        "verification": "verified",
        "act": {
          "act_id": "de:lukrfruherkv",
          "title": "Lungenkrebs-Früherkennungs-Verordnung (LuKrFrühErkV, 2024) — permissibility of low-dose CT for early detection of lung cancer",
          "short_title": "Lungenkrebs-Früherkennungs-Verordnung (LuKrFrühErkV, 2024) — permissibility of low-dose CT for early detection of lung cancer",
          "url": "https://www.gesetze-im-internet.de/lukrfr_herkv/",
          "binding": "national"
        }
      },
      "mitigations": [
        {
          "id": "mit.de.lung",
          "gap_id": "gap.de.lung.ahead",
          "kind": "research",
          "audience": "researchers",
          "summary": "Use the German programme as the real-world evaluation the Recommendation asks for, with a shared data model for pilots in other states.",
          "reference_measure_id": "de.scr.lung"
        }
      ]
    },
    {
      "id": "gap.de.secondopinion",
      "direction": "national_to_eu",
      "jurisdiction_code": "DE",
      "concept_id": "oncology.dx.second_opinion",
      "obligation_id": "eu.cbhc.reimbursement",
      "measure_id": "de.so.secondopinion",
      "gap_type": "national_only",
      "severity": 1,
      "summary": "A national statutory second-opinion right exists for listed interventions; there is no EU-level second-opinion right, and the German right does not extend to second-opinion providers abroad unless reimbursed under § 13 SGB V.",
      "verification": "needs_research",
      "status": "proposed",
      "reviewed_ledger_seq": null,
      "step": "Second opinion, cross-border diagnosis and ERN referral",
      "obligation": {
        "id": "eu.cbhc.reimbursement",
        "article": "Art. 7",
        "summary": "The Member State of affiliation reimburses cross-border healthcare up to the cost it would have paid domestically, if the care is among the patient's entitlements. Gatekeeping conditions (e.g. a GP assessment) may be imposed as for domestic care (Art. 7(7)).",
        "act": {
          "act_id": "celex:32011L0024",
          "title": "Directive 2011/24/EU on the application of patients' rights in cross-border healthcare",
          "short_title": "Directive 2011/24/EU (cross-border care)",
          "url": "https://eur-lex.europa.eu/eli/dir/2011/24/oj",
          "binding": "binding_transposition"
        }
      },
      "measure": {
        "id": "de.so.secondopinion",
        "article": "§ 27b SGB V with G-BA Zweitmeinungs-Richtlinie",
        "summary": "Statutory right to an independent second opinion before planned interventions on a G-BA list; which oncological procedures are covered must be checked against the current list.",
        "url": "https://www.gesetze-im-internet.de/sgb_5/__27b.html",
        "verification": "needs_research",
        "act": {
          "act_id": "de:sgb5",
          "title": "Sozialgesetzbuch Fünftes Buch (SGB V) — Gesetzliche Krankenversicherung",
          "short_title": "Sozialgesetzbuch Fünftes Buch (SGB V) — Gesetzliche Krankenversicherung",
          "url": "https://www.gesetze-im-internet.de/sgb_5/",
          "binding": "national"
        }
      },
      "mitigations": []
    },
    {
      "id": "gap.mdt.certification",
      "direction": "national_to_eu",
      "jurisdiction_code": "DE",
      "concept_id": "oncology.dx.staging_mdt",
      "obligation_id": "eu.ecibc.mdt",
      "measure_id": "de.mdt.dkg",
      "gap_type": "national_only",
      "severity": 1,
      "summary": "Quality of diagnostic work-up is signalled by national certification (DKG) that has no EU-level recognition, so it cannot be used as a cross-border quality criterion by NCPs or insurers.",
      "verification": "cited_unverified",
      "status": "proposed",
      "reviewed_ledger_seq": null,
      "step": "Staging and multidisciplinary tumour board",
      "obligation": {
        "id": "eu.ecibc.mdt",
        "article": "Quality assurance scheme requirements",
        "summary": "Breast cancer services discuss every case in a multidisciplinary team, meet diagnostic timeliness targets and report quality indicators.",
        "act": {
          "act_id": "eu:ecibc-qa-scheme",
          "title": "European Commission Initiative on Breast Cancer (ECIBC): European guidelines and quality assurance scheme for breast cancer services",
          "short_title": "ECIBC guidelines and QA scheme",
          "url": "https://cancer-screening-and-care.jrc.ec.europa.eu/en/ecibc",
          "binding": "soft_law"
        }
      },
      "measure": {
        "id": "de.mdt.dkg",
        "article": "DKG certification requirements",
        "summary": "Voluntary certification of organ cancer centres (e.g. breast centres) requiring tumour boards, minimum case volumes and quality indicators; widely used but not a statutory condition of payment.",
        "url": "https://www.krebsgesellschaft.de/zertdokumente.html",
        "verification": "cited_unverified",
        "act": {
          "act_id": "de:dkg-certification",
          "title": "German Cancer Society (DKG) certification of organ cancer centres and oncology centres (OnkoZert)",
          "short_title": "German Cancer Society (DKG) certification of organ cancer centres and oncology centres (OnkoZert)",
          "url": "https://www.krebsgesellschaft.de/zertdokumente.html",
          "binding": "voluntary"
        }
      },
      "mitigations": [
        {
          "id": "mit.mdt",
          "gap_id": "gap.mdt.certification",
          "kind": "policy",
          "audience": "eu",
          "summary": "Map DKG and SONCOS criteria onto the ECIBC quality assurance scheme so NCPs can publish comparable quality information (Directive Art. 4 and 6).",
          "reference_measure_id": null
        }
      ]
    },
    {
      "id": "gap.de.breast.age",
      "direction": "national_to_eu",
      "jurisdiction_code": "DE",
      "concept_id": "oncology.dx.screening.breast",
      "obligation_id": "eu.scr.breast",
      "measure_id": "de.scr.breast",
      "gap_type": "exceeds",
      "severity": 0,
      "summary": "Upper age 75 is above the core 50–69 band but within the optional 70–74 band plus one year; harmless for patients, relevant for research age-standardisation.",
      "verification": "needs_research",
      "status": "proposed",
      "reviewed_ledger_seq": null,
      "step": "Breast cancer screening (mammography)",
      "obligation": {
        "id": "eu.scr.breast",
        "article": "Point 1 and Annex (breast)",
        "summary": "Offer mammography screening to women aged 50–69; consider 45–49 and 70–74. MRI may be considered where medically appropriate (dense breasts).",
        "act": {
          "act_id": "celex:32022H1214(01)",
          "title": "Council Recommendation of 9 December 2022 on strengthening prevention through early detection: a new EU approach on cancer screening (2022/C 473/01)",
          "short_title": "Council Rec. 2022 on cancer screening",
          "url": "https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32022H1214(01)",
          "binding": "non_binding"
        }
      },
      "measure": {
        "id": "de.scr.breast",
        "article": "KFE-RL, mammography screening programme",
        "summary": "Biennial mammography screening for women 50–75 (upper age extended from 69 to 75 in 2024).",
        "url": "https://www.g-ba.de/richtlinien/17/",
        "verification": "needs_research",
        "act": {
          "act_id": "de:gba-kfe-rl",
          "title": "G-BA Krebsfrüherkennungs-Richtlinie (KFE-RL)",
          "short_title": "G-BA Krebsfrüherkennungs-Richtlinie (KFE-RL)",
          "url": "https://www.g-ba.de/richtlinien/17/",
          "binding": "national"
        }
      },
      "mitigations": []
    },
    {
      "id": "gap.de.registry.ahead",
      "direction": "national_to_eu",
      "jurisdiction_code": "DE",
      "concept_id": "oncology.dx.registry",
      "obligation_id": "eu.scr.quality",
      "measure_id": "de.reg.clinical",
      "gap_type": "exceeds",
      "severity": 0,
      "summary": "Mandatory clinical registries with treatment and outcome data go beyond EU requirements; a model for others, but the data model differs from ENCR population registries.",
      "verification": "cited_unverified",
      "status": "proposed",
      "reviewed_ledger_seq": null,
      "step": "Cancer registration",
      "obligation": {
        "id": "eu.scr.quality",
        "article": "Points on organisation, quality assurance and monitoring",
        "summary": "Run screening as population-based organised programmes with quality assurance at all levels, invitation systems, data systems linked to cancer registries, and report on implementation.",
        "act": {
          "act_id": "celex:32022H1214(01)",
          "title": "Council Recommendation of 9 December 2022 on strengthening prevention through early detection: a new EU approach on cancer screening (2022/C 473/01)",
          "short_title": "Council Rec. 2022 on cancer screening",
          "url": "https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32022H1214(01)",
          "binding": "non_binding"
        }
      },
      "measure": {
        "id": "de.reg.clinical",
        "article": "§ 65c SGB V; BKRG",
        "summary": "Mandatory clinical cancer registries in every Land with reporting duties for physicians and statutory funding; federal merging of registry data at the RKI cancer registry centre.",
        "url": "https://www.gesetze-im-internet.de/sgb_5/__65c.html",
        "verification": "cited_unverified",
        "act": {
          "act_id": "de:sgb5",
          "title": "Sozialgesetzbuch Fünftes Buch (SGB V) — Gesetzliche Krankenversicherung",
          "short_title": "Sozialgesetzbuch Fünftes Buch (SGB V) — Gesetzliche Krankenversicherung",
          "url": "https://www.gesetze-im-internet.de/sgb_5/",
          "binding": "national"
        }
      },
      "mitigations": []
    },
    {
      "id": "gap.nl.scr.cervical",
      "direction": "eu_to_national",
      "jurisdiction_code": "NL",
      "concept_id": "oncology.dx.screening.cervical",
      "obligation_id": "eu.scr.cervical",
      "measure_id": "nl.scr.cervical",
      "gap_type": "divergent",
      "severity": 1,
      "summary": "Upper age 60 rather than 65; otherwise aligned (HPV primary).",
      "verification": "cited_unverified",
      "status": "proposed",
      "reviewed_ledger_seq": null,
      "step": "Cervical cancer screening (HPV primary)",
      "obligation": {
        "id": "eu.scr.cervical",
        "article": "Point 1 and Annex (cervical)",
        "summary": "Offer HPV testing as the preferred primary test to women aged 30–65, at intervals of five years or more depending on vaccination history.",
        "act": {
          "act_id": "celex:32022H1214(01)",
          "title": "Council Recommendation of 9 December 2022 on strengthening prevention through early detection: a new EU approach on cancer screening (2022/C 473/01)",
          "short_title": "Council Rec. 2022 on cancer screening",
          "url": "https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32022H1214(01)",
          "binding": "non_binding"
        }
      },
      "measure": {
        "id": "nl.scr.cervical",
        "article": "National cervical cancer screening programme (RIVM-CvB)",
        "summary": "Primary hrHPV testing for women 30–60 (self-sampling available), with cytology triage.",
        "url": "https://www.rivm.nl/bevolkingsonderzoek-baarmoederhalskanker",
        "verification": "cited_unverified",
        "act": {
          "act_id": "nl:wbo",
          "title": "Wet op het bevolkingsonderzoek (WBO) — Population Screening Act",
          "short_title": "Wet op het bevolkingsonderzoek (WBO) — Population Screening Act",
          "url": "https://wetten.overheid.nl/BWBR0005699/",
          "binding": "national"
        }
      },
      "mitigations": []
    },
    {
      "id": "gap.nl.scr.colorectal",
      "direction": "eu_to_national",
      "jurisdiction_code": "NL",
      "concept_id": "oncology.dx.screening.colorectal",
      "obligation_id": "eu.scr.colorectal",
      "measure_id": "nl.scr.colorectal",
      "gap_type": "divergent",
      "severity": 1,
      "summary": "Programme starts at 55 instead of 50 (EU 50–74, NL 55–75). Results for people 50–54 are not comparable.",
      "verification": "verified",
      "status": "proposed",
      "reviewed_ledger_seq": null,
      "step": "Colorectal cancer screening (FIT)",
      "obligation": {
        "id": "eu.scr.colorectal",
        "article": "Point 1 and Annex (colorectal)",
        "summary": "Offer quantitative FIT screening to people aged 50–74 as the preferred triage test before endoscopic follow-up.",
        "act": {
          "act_id": "celex:32022H1214(01)",
          "title": "Council Recommendation of 9 December 2022 on strengthening prevention through early detection: a new EU approach on cancer screening (2022/C 473/01)",
          "short_title": "Council Rec. 2022 on cancer screening",
          "url": "https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32022H1214(01)",
          "binding": "non_binding"
        }
      },
      "measure": {
        "id": "nl.scr.colorectal",
        "article": "WBO permit for the colorectal cancer screening programme",
        "summary": "Biennial FIT for people 55–75 with colonoscopy after a positive test.",
        "url": "https://www.rivm.nl/sites/default/files/2026-06/Uitvoeringskader-bvo-DK-versie-15.0.pdf",
        "verification": "verified",
        "act": {
          "act_id": "nl:wbo",
          "title": "Wet op het bevolkingsonderzoek (WBO) — Population Screening Act",
          "short_title": "Wet op het bevolkingsonderzoek (WBO) — Population Screening Act",
          "url": "https://wetten.overheid.nl/BWBR0005699/",
          "binding": "national"
        }
      },
      "mitigations": []
    },
    {
      "id": "gap.nl.scr.lung",
      "direction": "eu_to_national",
      "jurisdiction_code": "NL",
      "concept_id": "oncology.dx.screening.lung",
      "obligation_id": "eu.scr.lung",
      "measure_id": null,
      "gap_type": "partial",
      "severity": 1,
      "summary": "No national programme; evaluation happens in research settings (NL hosted the NELSON trial) and any programme would need a WBO permit.",
      "verification": "needs_research",
      "status": "proposed",
      "reviewed_ledger_seq": null,
      "step": "Lung cancer screening (low-dose CT)",
      "obligation": {
        "id": "eu.scr.lung",
        "article": "Point 2 (lung)",
        "summary": "Explore the feasibility and effectiveness of low-dose CT screening for heavy smokers and ex-smokers, stepwise, starting with research and pilots and linked to smoking cessation.",
        "act": {
          "act_id": "celex:32022H1214(01)",
          "title": "Council Recommendation of 9 December 2022 on strengthening prevention through early detection: a new EU approach on cancer screening (2022/C 473/01)",
          "short_title": "Council Rec. 2022 on cancer screening",
          "url": "https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32022H1214(01)",
          "binding": "non_binding"
        }
      },
      "measure": null,
      "mitigations": []
    },
    {
      "id": "gap.nl.scr.prostate",
      "direction": "eu_to_national",
      "jurisdiction_code": "NL",
      "concept_id": "oncology.dx.screening.prostate",
      "obligation_id": "eu.scr.prostate",
      "measure_id": null,
      "gap_type": "partial",
      "severity": 1,
      "summary": "No organised programme; research and pilot stage only.",
      "verification": "needs_research",
      "status": "proposed",
      "reviewed_ledger_seq": null,
      "step": "Prostate cancer screening (PSA with MRI)",
      "obligation": {
        "id": "eu.scr.prostate",
        "article": "Point 2 (prostate)",
        "summary": "Evaluate organised prostate screening for men up to 70 based on PSA testing combined with MRI follow-up, stepwise, through research and pilots.",
        "act": {
          "act_id": "celex:32022H1214(01)",
          "title": "Council Recommendation of 9 December 2022 on strengthening prevention through early detection: a new EU approach on cancer screening (2022/C 473/01)",
          "short_title": "Council Rec. 2022 on cancer screening",
          "url": "https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32022H1214(01)",
          "binding": "non_binding"
        }
      },
      "measure": null,
      "mitigations": []
    },
    {
      "id": "gap.nl.scr.gastric",
      "direction": "eu_to_national",
      "jurisdiction_code": "NL",
      "concept_id": "oncology.dx.screening.gastric",
      "obligation_id": "eu.scr.gastric",
      "measure_id": null,
      "gap_type": "not_applicable",
      "severity": 0,
      "summary": "Recommendation targets high-incidence settings; the Netherlands is a low-incidence country.",
      "verification": "needs_research",
      "status": "proposed",
      "reviewed_ledger_seq": null,
      "step": "Gastric cancer screening (H. pylori screen-and-treat)",
      "obligation": {
        "id": "eu.scr.gastric",
        "article": "Point 2 (gastric)",
        "summary": "Consider H. pylori screen-and-treat in countries or regions with high gastric cancer incidence and mortality, and surveillance of pre-cancerous lesions.",
        "act": {
          "act_id": "celex:32022H1214(01)",
          "title": "Council Recommendation of 9 December 2022 on strengthening prevention through early detection: a new EU approach on cancer screening (2022/C 473/01)",
          "short_title": "Council Rec. 2022 on cancer screening",
          "url": "https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32022H1214(01)",
          "binding": "non_binding"
        }
      },
      "measure": null,
      "mitigations": []
    },
    {
      "id": "gap.nl.gatekeeping",
      "direction": "national_to_eu",
      "jurisdiction_code": "NL",
      "concept_id": "oncology.dx.referral",
      "obligation_id": "eu.cbhc.prescriptions",
      "measure_id": "nl.ref.gatekeeping",
      "gap_type": "national_only",
      "severity": 2,
      "summary": "GP referral is a condition of reimbursement; Art. 7(7) allows this, but referral notes are not covered by EU mutual recognition (Art. 11 covers prescriptions only), so a referral issued abroad may not be accepted.",
      "verification": "needs_research",
      "status": "proposed",
      "reviewed_ledger_seq": null,
      "step": "Symptomatic presentation and referral",
      "obligation": {
        "id": "eu.cbhc.prescriptions",
        "article": "Art. 11 with Implementing Directive 2012/52/EU",
        "summary": "Prescriptions for medicinal products and medical devices issued in another Member State are recognised. Referral notes for diagnostics are not covered by this mechanism.",
        "act": {
          "act_id": "celex:32011L0024",
          "title": "Directive 2011/24/EU on the application of patients' rights in cross-border healthcare",
          "short_title": "Directive 2011/24/EU (cross-border care)",
          "url": "https://eur-lex.europa.eu/eli/dir/2011/24/oj",
          "binding": "binding_transposition"
        }
      },
      "measure": {
        "id": "nl.ref.gatekeeping",
        "article": "Besluit zorgverzekering (referral for specialist care)",
        "summary": "Specialist medical care is reimbursed on referral by a GP (gatekeeper model).",
        "url": "https://wetten.overheid.nl/BWBR0018492/",
        "verification": "needs_research",
        "act": {
          "act_id": "nl:zvw",
          "title": "Zorgverzekeringswet (Zvw) — Health Insurance Act",
          "short_title": "Zorgverzekeringswet (Zvw) — Health Insurance Act",
          "url": "https://wetten.overheid.nl/BWBR0018450/",
          "binding": "national"
        }
      },
      "mitigations": [
        {
          "id": "mit.nl.referral",
          "gap_id": "gap.nl.gatekeeping",
          "kind": "policy",
          "audience": "insurer",
          "summary": "Insurers can state in policy conditions that a referral from a physician in another Member State is accepted.",
          "reference_measure_id": null
        }
      ]
    },
    {
      "id": "gap.nl.wbo.permit",
      "direction": "national_to_eu",
      "jurisdiction_code": "NL",
      "concept_id": "oncology.dx.screening",
      "obligation_id": "eu.bss.justification",
      "measure_id": "nl.scr.wbo",
      "gap_type": "exceeds",
      "severity": 2,
      "summary": "The WBO permit regime goes beyond the BSS justification rule: any cancer screening offer, including commercial or AI-supported screening, needs a permit. This is a market-access barrier specific to the Netherlands.",
      "verification": "secondary",
      "status": "proposed",
      "reviewed_ledger_seq": null,
      "step": "Organised population screening",
      "obligation": {
        "id": "eu.bss.justification",
        "article": "Art. 55",
        "summary": "Every medical exposure must be justified, generically and individually. A radiological procedure on an asymptomatic person for early detection must be part of a health screening programme or have a specific documented justification.",
        "act": {
          "act_id": "celex:32013L0059",
          "title": "Council Directive 2013/59/Euratom laying down basic safety standards for protection against the dangers arising from exposure to ionising radiation (BSS)",
          "short_title": "Directive 2013/59/Euratom (BSS)",
          "url": "https://eur-lex.europa.eu/eli/dir/2013/59/oj",
          "binding": "binding_transposition"
        }
      },
      "measure": {
        "id": "nl.scr.wbo",
        "article": "WBO, permit requirement",
        "summary": "Population screening for cancer, or using ionising radiation, needs a ministerial permit after advice of the Health Council (Gezondheidsraad). This also covers commercial screening offers.",
        "url": "https://wetten.overheid.nl/BWBR0005699/",
        "verification": "secondary",
        "act": {
          "act_id": "nl:wbo",
          "title": "Wet op het bevolkingsonderzoek (WBO) — Population Screening Act",
          "short_title": "Wet op het bevolkingsonderzoek (WBO) — Population Screening Act",
          "url": "https://wetten.overheid.nl/BWBR0005699/",
          "binding": "national"
        }
      },
      "mitigations": [
        {
          "id": "mit.nl.wbo",
          "gap_id": "gap.nl.wbo.permit",
          "kind": "medtech",
          "audience": "medtech",
          "summary": "Plan WBO permit timelines (Health Council advice) in NL market entry for any screening use; position AI tools inside the national programme rather than as stand-alone screening.",
          "reference_measure_id": null
        }
      ]
    },
    {
      "id": "gap.nl.soncos",
      "direction": "national_to_eu",
      "jurisdiction_code": "NL",
      "concept_id": "oncology.dx.staging_mdt",
      "obligation_id": "eu.ecibc.mdt",
      "measure_id": "nl.mdt.soncos",
      "gap_type": "national_only",
      "severity": 1,
      "summary": "SONCOS volume norms steer purchasing but are national only; no mapping to ECIBC accreditation.",
      "verification": "cited_unverified",
      "status": "proposed",
      "reviewed_ledger_seq": null,
      "step": "Staging and multidisciplinary tumour board",
      "obligation": {
        "id": "eu.ecibc.mdt",
        "article": "Quality assurance scheme requirements",
        "summary": "Breast cancer services discuss every case in a multidisciplinary team, meet diagnostic timeliness targets and report quality indicators.",
        "act": {
          "act_id": "eu:ecibc-qa-scheme",
          "title": "European Commission Initiative on Breast Cancer (ECIBC): European guidelines and quality assurance scheme for breast cancer services",
          "short_title": "ECIBC guidelines and QA scheme",
          "url": "https://cancer-screening-and-care.jrc.ec.europa.eu/en/ecibc",
          "binding": "soft_law"
        }
      },
      "measure": {
        "id": "nl.mdt.soncos",
        "article": "SONCOS standards",
        "summary": "Professional multidisciplinary standards incl. tumour boards and minimum volumes, used by insurers in purchasing.",
        "url": "https://www.soncos.org/kwaliteit/normeringsrapport/",
        "verification": "cited_unverified",
        "act": {
          "act_id": "nl:soncos",
          "title": "SONCOS Normeringsrapport — multidisciplinary quality standards for oncological care",
          "short_title": "SONCOS Normeringsrapport — multidisciplinary quality standards for oncological care",
          "url": "https://www.soncos.org/kwaliteit/normeringsrapport/",
          "binding": "voluntary"
        }
      },
      "mitigations": []
    },
    {
      "id": "gap.nl.wbmv",
      "direction": "national_to_eu",
      "jurisdiction_code": "NL",
      "concept_id": "oncology.dx.biomarker.germline",
      "obligation_id": "eu.ivdr.devices",
      "measure_id": "nl.gen.wbmv",
      "gap_type": "national_only",
      "severity": 1,
      "summary": "Germline testing concentrated in licensed clinical genetics centres; a CE-marked test alone does not give market access to clinical use.",
      "verification": "secondary",
      "status": "proposed",
      "reviewed_ledger_seq": null,
      "step": "Germline genetic testing for hereditary cancer",
      "obligation": {
        "id": "eu.ivdr.devices",
        "article": "Art. 5, Art. 48, Annex VIII",
        "summary": "IVDs (FIT, HPV tests, PSA assays, IHC and molecular tests) must be CE-marked; cancer tests and companion diagnostics are generally class C and need a notified body, with EMA or national medicines authority consultation for companion diagnostics.",
        "act": {
          "act_id": "celex:32017R0746",
          "title": "Regulation (EU) 2017/746 on in vitro diagnostic medical devices (IVDR)",
          "short_title": "Reg. 2017/746 (IVDR)",
          "url": "https://eur-lex.europa.eu/eli/reg/2017/746/oj",
          "binding": "directly_applicable"
        }
      },
      "measure": {
        "id": "nl.gen.wbmv",
        "article": "WBMV licensing of clinical genetic testing",
        "summary": "Clinical genetic testing (incl. hereditary cancer DNA diagnostics) is a licensed special medical procedure concentrated in the clinical genetics centres.",
        "url": "https://www.rijksoverheid.nl/themas/familie-zorg-en-gezondheid/kwaliteit-van-de-zorg/vergunning-bijzondere-medische-verrichtingen-ziekenhuizen",
        "verification": "secondary",
        "act": {
          "act_id": "nl:wbmv",
          "title": "Wet op bijzondere medische verrichtingen (WBMV) — licensing of special medical procedures incl. clinical genetic testing",
          "short_title": "Wet op bijzondere medische verrichtingen (WBMV) — licensing of special medical procedures incl. clinical genetic testing",
          "url": "https://www.rijksoverheid.nl/themas/familie-zorg-en-gezondheid/kwaliteit-van-de-zorg/vergunning-bijzondere-medische-verrichtingen-ziekenhuizen",
          "binding": "national"
        }
      },
      "mitigations": []
    },
    {
      "id": "gap.nl.breast.age",
      "direction": "national_to_eu",
      "jurisdiction_code": "NL",
      "concept_id": "oncology.dx.screening.breast",
      "obligation_id": "eu.scr.breast",
      "measure_id": "nl.scr.breast",
      "gap_type": "exceeds",
      "severity": 0,
      "summary": "Upper age 75, as in Germany; age-band harmonisation needed when comparing interval cancers.",
      "verification": "cited_unverified",
      "status": "proposed",
      "reviewed_ledger_seq": null,
      "step": "Breast cancer screening (mammography)",
      "obligation": {
        "id": "eu.scr.breast",
        "article": "Point 1 and Annex (breast)",
        "summary": "Offer mammography screening to women aged 50–69; consider 45–49 and 70–74. MRI may be considered where medically appropriate (dense breasts).",
        "act": {
          "act_id": "celex:32022H1214(01)",
          "title": "Council Recommendation of 9 December 2022 on strengthening prevention through early detection: a new EU approach on cancer screening (2022/C 473/01)",
          "short_title": "Council Rec. 2022 on cancer screening",
          "url": "https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32022H1214(01)",
          "binding": "non_binding"
        }
      },
      "measure": {
        "id": "nl.scr.breast",
        "article": "National breast cancer screening programme (RIVM-CvB)",
        "summary": "Biennial mammography for women 50–75.",
        "url": "https://www.rivm.nl/bevolkingsonderzoek-borstkanker",
        "verification": "cited_unverified",
        "act": {
          "act_id": "nl:wbo",
          "title": "Wet op het bevolkingsonderzoek (WBO) — Population Screening Act",
          "short_title": "Wet op het bevolkingsonderzoek (WBO) — Population Screening Act",
          "url": "https://wetten.overheid.nl/BWBR0005699/",
          "binding": "national"
        }
      },
      "mitigations": []
    },
    {
      "id": "gap.ro.registry",
      "direction": "eu_to_national",
      "jurisdiction_code": "RO",
      "concept_id": "oncology.dx.registry",
      "obligation_id": "eu.scr.quality",
      "measure_id": "ro.reg.rnc",
      "gap_type": "delayed",
      "severity": 3,
      "summary": "The national cancer registry framework exists only as a 2023 draft decision; without registry linkage, screening quality assurance and stage-at-diagnosis research are not possible at national level.",
      "verification": "secondary",
      "status": "proposed",
      "reviewed_ledger_seq": null,
      "step": "Cancer registration",
      "obligation": {
        "id": "eu.scr.quality",
        "article": "Points on organisation, quality assurance and monitoring",
        "summary": "Run screening as population-based organised programmes with quality assurance at all levels, invitation systems, data systems linked to cancer registries, and report on implementation.",
        "act": {
          "act_id": "celex:32022H1214(01)",
          "title": "Council Recommendation of 9 December 2022 on strengthening prevention through early detection: a new EU approach on cancer screening (2022/C 473/01)",
          "short_title": "Council Rec. 2022 on cancer screening",
          "url": "https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32022H1214(01)",
          "binding": "non_binding"
        }
      },
      "measure": {
        "id": "ro.reg.rnc",
        "article": "Draft HG on the National Cancer Registry",
        "summary": "Draft government decision (2023) to organise the national cancer registry; adoption status to be confirmed.",
        "url": "https://management-documente.ms.ro/media/documents/HG_-REGISTRUL_NATIONAL_DE_CANCER_-_25.07.2023_2okqVrf.docx",
        "verification": "verified",
        "act": {
          "act_id": "ro:draft-hg-rnc-2023",
          "title": "Proiect HG privind Registrul Național de Cancer (Ministerul Sănătății, July 2023)",
          "short_title": "Proiect HG privind Registrul Național de Cancer (Ministerul Sănătății, July 2023)",
          "url": "https://management-documente.ms.ro/media/documents/HG_-REGISTRUL_NATIONAL_DE_CANCER_-_25.07.2023_2okqVrf.docx",
          "binding": "draft"
        }
      },
      "mitigations": [
        {
          "id": "mit.ro.registry",
          "gap_id": "gap.ro.registry",
          "kind": "policy",
          "audience": "ministry",
          "summary": "Adopt the registry decision and align the data set with ENCR so it can later serve as an EHDS data holder.",
          "reference_measure_id": "de.reg.clinical"
        }
      ]
    },
    {
      "id": "gap.ro.scr.breast",
      "direction": "eu_to_national",
      "jurisdiction_code": "RO",
      "concept_id": "oncology.dx.screening.breast",
      "obligation_id": "eu.scr.breast",
      "measure_id": "ro.scr.breast",
      "gap_type": "partial",
      "severity": 3,
      "summary": "No permanent nationwide population-based breast screening programme; coverage depends on time-limited, region-based EU-funded projects.",
      "verification": "secondary",
      "status": "proposed",
      "reviewed_ledger_seq": null,
      "step": "Breast cancer screening (mammography)",
      "obligation": {
        "id": "eu.scr.breast",
        "article": "Point 1 and Annex (breast)",
        "summary": "Offer mammography screening to women aged 50–69; consider 45–49 and 70–74. MRI may be considered where medically appropriate (dense breasts).",
        "act": {
          "act_id": "celex:32022H1214(01)",
          "title": "Council Recommendation of 9 December 2022 on strengthening prevention through early detection: a new EU approach on cancer screening (2022/C 473/01)",
          "short_title": "Council Rec. 2022 on cancer screening",
          "url": "https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32022H1214(01)",
          "binding": "non_binding"
        }
      },
      "measure": {
        "id": "ro.scr.breast",
        "article": "Programul Sănătate, Action 8 (regional breast screening and diagnosis)",
        "summary": "Breast cancer screening organised through EU-funded regional programmes rather than one permanent nationwide population programme.",
        "url": "https://www.adrcentru.ro/wp-content/uploads/2025/08/AP8.-Programul-Sanatate-Organizarea-unui-Program-national-de-prevenire-depistare-precoce-screening-si-diagnostic-al-cancerului-la-san.pdf",
        "verification": "secondary",
        "act": {
          "act_id": "ro:pncc-programme-sanatate",
          "title": "Programul Sănătate 2021–2027, regional breast cancer screening and diagnosis programmes (EU cohesion funding)",
          "short_title": "Programul Sănătate 2021–2027, regional breast cancer screening and diagnosis programmes (EU cohesion funding)",
          "url": "https://www.adrcentru.ro/wp-content/uploads/2025/08/AP8.-Programul-Sanatate-Organizarea-unui-Program-national-de-prevenire-depistare-precoce-screening-si-diagnostic-al-cancerului-la-san.pdf",
          "binding": "national"
        }
      },
      "mitigations": [
        {
          "id": "mit.ro.scr.breast",
          "gap_id": "gap.ro.scr.breast",
          "kind": "policy",
          "audience": "ministry",
          "summary": "Turn the regional projects into a permanent population programme with a national invitation register and ECIBC accreditation; the NL and DE programmes are working references.",
          "reference_measure_id": "nl.scr.breast"
        }
      ]
    },
    {
      "id": "gap.ro.scr.colorectal",
      "direction": "eu_to_national",
      "jurisdiction_code": "RO",
      "concept_id": "oncology.dx.screening.colorectal",
      "obligation_id": "eu.scr.colorectal",
      "measure_id": "ro.scr.colorectal",
      "gap_type": "partial",
      "severity": 3,
      "summary": "FIT-based organised screening for 50–74 is not available nationally; only pilots.",
      "verification": "needs_research",
      "status": "proposed",
      "reviewed_ledger_seq": null,
      "step": "Colorectal cancer screening (FIT)",
      "obligation": {
        "id": "eu.scr.colorectal",
        "article": "Point 1 and Annex (colorectal)",
        "summary": "Offer quantitative FIT screening to people aged 50–74 as the preferred triage test before endoscopic follow-up.",
        "act": {
          "act_id": "celex:32022H1214(01)",
          "title": "Council Recommendation of 9 December 2022 on strengthening prevention through early detection: a new EU approach on cancer screening (2022/C 473/01)",
          "short_title": "Council Rec. 2022 on cancer screening",
          "url": "https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32022H1214(01)",
          "binding": "non_binding"
        }
      },
      "measure": {
        "id": "ro.scr.colorectal",
        "article": "Regional colorectal screening projects",
        "summary": "Colorectal screening limited to regional, project-based pilots.",
        "url": null,
        "verification": "needs_research",
        "act": {
          "act_id": "ro:pncc-programme-sanatate",
          "title": "Programul Sănătate 2021–2027, regional breast cancer screening and diagnosis programmes (EU cohesion funding)",
          "short_title": "Programul Sănătate 2021–2027, regional breast cancer screening and diagnosis programmes (EU cohesion funding)",
          "url": "https://www.adrcentru.ro/wp-content/uploads/2025/08/AP8.-Programul-Sanatate-Organizarea-unui-Program-national-de-prevenire-depistare-precoce-screening-si-diagnostic-al-cancerului-la-san.pdf",
          "binding": "national"
        }
      },
      "mitigations": [
        {
          "id": "mit.ro.scr.colorectal",
          "gap_id": "gap.ro.scr.colorectal",
          "kind": "implementation",
          "audience": "ministry",
          "summary": "Adopt FIT with a quantitative cut-off and colonoscopy capacity planning, as in the NL programme's implementation framework.",
          "reference_measure_id": "nl.scr.colorectal"
        }
      ]
    },
    {
      "id": "gap.eu.ehds.timeline",
      "direction": "eu_to_national",
      "jurisdiction_code": "RO",
      "concept_id": "oncology.dx.records",
      "obligation_id": "eu.ehds.primary",
      "measure_id": null,
      "gap_type": "unclear",
      "severity": 2,
      "summary": "No national roadmap located for exchanging imaging reports and laboratory results in the European EHR exchange format; the existing national electronic health record covers insured persons' data through the insurance IT platform.",
      "verification": "needs_research",
      "status": "proposed",
      "reviewed_ledger_seq": null,
      "step": "Diagnostic reports and health-record exchange",
      "obligation": {
        "id": "eu.ehds.primary",
        "article": "Art. 14 (priority categories) and European EHR exchange format",
        "summary": "Patients get electronic access to and exchange of priority categories: patient summaries and e-prescriptions first, then medical images and imaging reports, laboratory results and discharge reports, in the European EHR exchange format (staged application, about 2029 and 2031).",
        "act": {
          "act_id": "celex:32025R0327",
          "title": "Regulation (EU) 2025/327 on the European Health Data Space",
          "short_title": "Reg. 2025/327 (EHDS)",
          "url": "https://eur-lex.europa.eu/eli/reg/2025/327/oj",
          "binding": "directly_applicable"
        }
      },
      "measure": null,
      "mitigations": [
        {
          "id": "mit.ro.ehds",
          "gap_id": "gap.eu.ehds.timeline",
          "kind": "technical",
          "audience": "ministry",
          "summary": "Publish a roadmap for imaging and laboratory report exchange in the European EHR exchange format, building on national experience with image exchange.",
          "reference_measure_id": "nl.rec.wegiz"
        }
      ]
    },
    {
      "id": "gap.ro.ivdr.inhouse",
      "direction": "eu_to_national",
      "jurisdiction_code": "RO",
      "concept_id": "oncology.dx.biomarker",
      "obligation_id": "eu.ivdr.inhouse",
      "measure_id": "ro.dev.anmdmr",
      "gap_type": "unclear",
      "severity": 2,
      "summary": "No national guidance located on how hospital laboratories document in-house tests under IVDR Art. 5(5), which matters for molecular pathology.",
      "verification": "needs_research",
      "status": "proposed",
      "reviewed_ledger_seq": null,
      "step": "Tumour biomarker and molecular testing",
      "obligation": {
        "id": "eu.ivdr.inhouse",
        "article": "Art. 5(5) (as amended by Regulation (EU) 2024/1860 for transitional dates)",
        "summary": "Health institutions may make and use in-house tests (laboratory-developed tests) only under the Art. 5(5) conditions: no transfer to another legal entity, appropriate quality management, documentation, and justification that no equivalent CE-marked device meets the patient group's needs (later application date).",
        "act": {
          "act_id": "celex:32017R0746",
          "title": "Regulation (EU) 2017/746 on in vitro diagnostic medical devices (IVDR)",
          "short_title": "Reg. 2017/746 (IVDR)",
          "url": "https://eur-lex.europa.eu/eli/reg/2017/746/oj",
          "binding": "directly_applicable"
        }
      },
      "measure": {
        "id": "ro.dev.anmdmr",
        "article": "Legea 95/2006 (medical devices title) and ANMDMR rules",
        "summary": "ANMDMR is the competent authority for medical devices and IVDs; national provisions for in-house tests in hospital laboratories not located.",
        "url": "https://www.anm.ro",
        "verification": "needs_research",
        "act": {
          "act_id": "ro:legea-95-2006",
          "title": "Legea nr. 95/2006 privind reforma în domeniul sănătății (republished, as amended)",
          "short_title": "Legea nr. 95/2006 privind reforma în domeniul sănătății (republished, as amended)",
          "url": "https://legislatie.just.ro/Public/DetaliiDocument/71139",
          "binding": "national"
        }
      },
      "mitigations": [
        {
          "id": "mit.ro.ivdr",
          "gap_id": "gap.ro.ivdr.inhouse",
          "kind": "medtech",
          "audience": "laboratories",
          "summary": "Template documentation pack for Art. 5(5) in-house tests, or a CE-marked equivalent offer for common biomarker panels.",
          "reference_measure_id": null
        }
      ]
    },
    {
      "id": "gap.ro.scr.cervical",
      "direction": "eu_to_national",
      "jurisdiction_code": "RO",
      "concept_id": "oncology.dx.screening.cervical",
      "obligation_id": "eu.scr.cervical",
      "measure_id": "ro.scr.cervical",
      "gap_type": "divergent",
      "severity": 2,
      "summary": "Cytology remains the primary test in the national programme, whereas the Recommendation prefers HPV primary testing; participation reported as low.",
      "verification": "needs_research",
      "status": "proposed",
      "reviewed_ledger_seq": null,
      "step": "Cervical cancer screening (HPV primary)",
      "obligation": {
        "id": "eu.scr.cervical",
        "article": "Point 1 and Annex (cervical)",
        "summary": "Offer HPV testing as the preferred primary test to women aged 30–65, at intervals of five years or more depending on vaccination history.",
        "act": {
          "act_id": "celex:32022H1214(01)",
          "title": "Council Recommendation of 9 December 2022 on strengthening prevention through early detection: a new EU approach on cancer screening (2022/C 473/01)",
          "short_title": "Council Rec. 2022 on cancer screening",
          "url": "https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32022H1214(01)",
          "binding": "non_binding"
        }
      },
      "measure": {
        "id": "ro.scr.cervical",
        "article": "National health programmes: cervical screening sub-programme",
        "summary": "Cervical cancer screening within the national health programmes, historically cytology (Babeș-Papanicolaou) based; HPV primary testing is being introduced through EU-funded projects.",
        "url": "https://ms.ro/media/documents/NF_HG_423_2022_PNS.pdf",
        "verification": "needs_research",
        "act": {
          "act_id": "ro:hg-423-2022",
          "title": "HG nr. 423/2022 privind aprobarea programelor naționale de sănătate",
          "short_title": "HG nr. 423/2022 privind aprobarea programelor naționale de sănătate",
          "url": "https://ms.ro/media/documents/NF_HG_423_2022_PNS.pdf",
          "binding": "national"
        }
      },
      "mitigations": [
        {
          "id": "mit.ro.cervical",
          "gap_id": "gap.ro.scr.cervical",
          "kind": "implementation",
          "audience": "ministry",
          "summary": "Switch to HPV primary testing with self-sampling to raise participation.",
          "reference_measure_id": "nl.scr.cervical"
        }
      ]
    },
    {
      "id": "gap.ro.scr.gastric",
      "direction": "eu_to_national",
      "jurisdiction_code": "RO",
      "concept_id": "oncology.dx.screening.gastric",
      "obligation_id": "eu.scr.gastric",
      "measure_id": null,
      "gap_type": "not_implemented",
      "severity": 2,
      "summary": "Romania is among the EU countries with higher gastric cancer burden, so the screen-and-treat recommendation is relevant, but no programme or pilot was located.",
      "verification": "needs_research",
      "status": "proposed",
      "reviewed_ledger_seq": null,
      "step": "Gastric cancer screening (H. pylori screen-and-treat)",
      "obligation": {
        "id": "eu.scr.gastric",
        "article": "Point 2 (gastric)",
        "summary": "Consider H. pylori screen-and-treat in countries or regions with high gastric cancer incidence and mortality, and surveillance of pre-cancerous lesions.",
        "act": {
          "act_id": "celex:32022H1214(01)",
          "title": "Council Recommendation of 9 December 2022 on strengthening prevention through early detection: a new EU approach on cancer screening (2022/C 473/01)",
          "short_title": "Council Rec. 2022 on cancer screening",
          "url": "https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32022H1214(01)",
          "binding": "non_binding"
        }
      },
      "measure": null,
      "mitigations": []
    },
    {
      "id": "gap.ro.cb.ncp",
      "direction": "eu_to_national",
      "jurisdiction_code": "RO",
      "concept_id": "oncology.dx.second_opinion",
      "obligation_id": "eu.cbhc.ncp",
      "measure_id": "ro.cb.ncp",
      "gap_type": "unclear",
      "severity": 1,
      "summary": "The NCP's published information on which diagnostic procedures need prior authorisation was not located in this pass.",
      "verification": "needs_research",
      "status": "proposed",
      "reviewed_ledger_seq": null,
      "step": "Second opinion, cross-border diagnosis and ERN referral",
      "obligation": {
        "id": "eu.cbhc.ncp",
        "article": "Art. 6",
        "summary": "Each Member State designates national contact points that inform patients on rights, providers, quality standards and reimbursement.",
        "act": {
          "act_id": "celex:32011L0024",
          "title": "Directive 2011/24/EU on the application of patients' rights in cross-border healthcare",
          "short_title": "Directive 2011/24/EU (cross-border care)",
          "url": "https://eur-lex.europa.eu/eli/dir/2011/24/oj",
          "binding": "binding_transposition"
        }
      },
      "measure": {
        "id": "ro.cb.ncp",
        "article": "National contact point (CNAS)",
        "summary": "National contact point for cross-border healthcare within CNAS.",
        "url": "https://cnas.ro",
        "verification": "needs_research",
        "act": {
          "act_id": "ro:hg-304-2014",
          "title": "HG nr. 304/2014 pentru aprobarea Normelor metodologice privind asistența medicală transfrontalieră",
          "short_title": "HG nr. 304/2014 pentru aprobarea Normelor metodologice privind asistența medicală transfrontalieră",
          "url": "https://legeaz.net/monitorul-oficial-318-2014/hg-304-2014-107-din-27022014",
          "binding": "national"
        }
      },
      "mitigations": []
    },
    {
      "id": "gap.ro.scr.lung",
      "direction": "eu_to_national",
      "jurisdiction_code": "RO",
      "concept_id": "oncology.dx.screening.lung",
      "obligation_id": "eu.scr.lung",
      "measure_id": null,
      "gap_type": "not_implemented",
      "severity": 1,
      "summary": "No national evaluation or pilot of LDCT lung screening located.",
      "verification": "needs_research",
      "status": "proposed",
      "reviewed_ledger_seq": null,
      "step": "Lung cancer screening (low-dose CT)",
      "obligation": {
        "id": "eu.scr.lung",
        "article": "Point 2 (lung)",
        "summary": "Explore the feasibility and effectiveness of low-dose CT screening for heavy smokers and ex-smokers, stepwise, starting with research and pilots and linked to smoking cessation.",
        "act": {
          "act_id": "celex:32022H1214(01)",
          "title": "Council Recommendation of 9 December 2022 on strengthening prevention through early detection: a new EU approach on cancer screening (2022/C 473/01)",
          "short_title": "Council Rec. 2022 on cancer screening",
          "url": "https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32022H1214(01)",
          "binding": "non_binding"
        }
      },
      "measure": null,
      "mitigations": []
    },
    {
      "id": "gap.ro.scr.prostate",
      "direction": "eu_to_national",
      "jurisdiction_code": "RO",
      "concept_id": "oncology.dx.screening.prostate",
      "obligation_id": "eu.scr.prostate",
      "measure_id": null,
      "gap_type": "not_implemented",
      "severity": 1,
      "summary": "No organised PSA+MRI evaluation located.",
      "verification": "needs_research",
      "status": "proposed",
      "reviewed_ledger_seq": null,
      "step": "Prostate cancer screening (PSA with MRI)",
      "obligation": {
        "id": "eu.scr.prostate",
        "article": "Point 2 (prostate)",
        "summary": "Evaluate organised prostate screening for men up to 70 based on PSA testing combined with MRI follow-up, stepwise, through research and pilots.",
        "act": {
          "act_id": "celex:32022H1214(01)",
          "title": "Council Recommendation of 9 December 2022 on strengthening prevention through early detection: a new EU approach on cancer screening (2022/C 473/01)",
          "short_title": "Council Rec. 2022 on cancer screening",
          "url": "https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32022H1214(01)",
          "binding": "non_binding"
        }
      },
      "measure": null,
      "mitigations": []
    },
    {
      "id": "gap.ro.bilet",
      "direction": "national_to_eu",
      "jurisdiction_code": "RO",
      "concept_id": "oncology.dx.referral",
      "obligation_id": "eu.cbhc.prescriptions",
      "measure_id": "ro.ref.bilet",
      "gap_type": "national_only",
      "severity": 2,
      "summary": "CNAS-paid diagnostics need a Romanian referral note from a contracted physician and depend on provider budgets; a referral from another Member State has no recognition route, which complicates diagnostic follow-up of mobile patients.",
      "verification": "cited_unverified",
      "status": "proposed",
      "reviewed_ledger_seq": null,
      "step": "Symptomatic presentation and referral",
      "obligation": {
        "id": "eu.cbhc.prescriptions",
        "article": "Art. 11 with Implementing Directive 2012/52/EU",
        "summary": "Prescriptions for medicinal products and medical devices issued in another Member State are recognised. Referral notes for diagnostics are not covered by this mechanism.",
        "act": {
          "act_id": "celex:32011L0024",
          "title": "Directive 2011/24/EU on the application of patients' rights in cross-border healthcare",
          "short_title": "Directive 2011/24/EU (cross-border care)",
          "url": "https://eur-lex.europa.eu/eli/dir/2011/24/oj",
          "binding": "binding_transposition"
        }
      },
      "measure": {
        "id": "ro.ref.bilet",
        "article": "Contract-cadru and norms (bilet de trimitere)",
        "summary": "Paraclinical investigations (imaging, laboratory) paid by CNAS need a referral note (bilet de trimitere) from a contracted physician and are limited by monthly provider budgets.",
        "url": "https://legislatie.just.ro/Public/DetaliiDocument/300314",
        "verification": "cited_unverified",
        "act": {
          "act_id": "ro:hg-521-2023",
          "title": "Hotărârea Guvernului nr. 521/2023 pentru aprobarea pachetelor de servicii și a Contractului-cadru",
          "short_title": "Hotărârea Guvernului nr. 521/2023 pentru aprobarea pachetelor de servicii și a Contractului-cadru",
          "url": "https://legislatie.just.ro/Public/DetaliiDocument/300314",
          "binding": "national"
        }
      },
      "mitigations": [
        {
          "id": "mit.referral",
          "gap_id": "gap.ro.bilet",
          "kind": "policy",
          "audience": "eu",
          "summary": "Extend mutual recognition (Art. 11 logic) to diagnostic referral notes, or allow a cross-border referral in the European EHR exchange format.",
          "reference_measure_id": null
        }
      ]
    },
    {
      "id": "gap.ro.petct.budget",
      "direction": "national_to_eu",
      "jurisdiction_code": "RO",
      "concept_id": "oncology.dx.imaging.pet_ct",
      "obligation_id": "eu.s2.planned",
      "measure_id": "ro.img.petct",
      "gap_type": "divergent",
      "severity": 2,
      "summary": "PET-CT access is capped by programme budgets. When waiting exceeds a medically justifiable time, Reg. 883/2004 Art. 20 obliges authorisation of S2 treatment abroad; this interaction is not documented in the national rules found.",
      "verification": "secondary",
      "status": "proposed",
      "reviewed_ledger_seq": null,
      "step": "PET-CT (nuclear medicine)",
      "obligation": {
        "id": "eu.s2.planned",
        "article": "Art. 20 with Reg. 987/2009 Art. 26",
        "summary": "Planned treatment abroad on an S2 form at the treating country's tariffs; authorisation must be granted when the treatment is an entitlement and cannot be given at home within a medically justifiable time.",
        "act": {
          "act_id": "celex:32004R0883",
          "title": "Regulation (EC) No 883/2004 on the coordination of social security systems",
          "short_title": "Reg. 883/2004 (social security)",
          "url": "https://eur-lex.europa.eu/eli/reg/2004/883/oj",
          "binding": "directly_applicable"
        }
      },
      "measure": {
        "id": "ro.img.petct",
        "article": "National oncology programme, PET-CT",
        "summary": "PET-CT for oncology patients funded through the national oncology programme with contracted providers; since 1 June 2023 the approval commission was removed, but access remains budget-capped per provider.",
        "url": "https://alba24.ro/pacientii-oncologici-vor-avea-mai-usor-acces-la-investigatiile-pet-ct-de-la-1-iunie-precizarile-cnas-980541.html",
        "verification": "secondary",
        "act": {
          "act_id": "ro:cnas-pet-ct-2023",
          "title": "CNAS measure of 2023 removing the approval commission for PET-CT in the national oncology programme (from 1 June 2023)",
          "short_title": "CNAS measure of 2023 removing the approval commission for PET-CT in the national oncology programme (from 1 June 2023)",
          "url": "https://alba24.ro/pacientii-oncologici-vor-avea-mai-usor-acces-la-investigatiile-pet-ct-de-la-1-iunie-precizarile-cnas-980541.html",
          "binding": "national"
        }
      },
      "mitigations": [
        {
          "id": "mit.ro.petct",
          "gap_id": "gap.ro.petct.budget",
          "kind": "implementation",
          "audience": "payer",
          "summary": "Publish waiting times for PET-CT and the S2 procedure when they exceed medically justifiable limits.",
          "reference_measure_id": null
        }
      ]
    }
  ],
  "disclaimer": "MVP research dataset compiled by hand from public legal sources; not legal or medical advice. Each row carries a verification level (verified, secondary, cited_unverified, needs_research); only \"verified\" rows were checked against the official text on the dataset date. Gap findings are \"proposed\" until reviewed."
}